Senotherapeutics—drugs that eliminate senescent cells—successfully reverse cardiac aging by reducing myocardial dysfunction, hypertrophy, and fibrosis while activating the heart's natural regenerative capacity. These interventions target the core pathology of aged hearts: accumulated senescent cells, chronic inflammation (inflammaging), and metabolic dysfunction that typically plague patients over 70. This represents a fundamental shift in cardiac regenerative medicine strategy. Rather than simply introducing new cells or growth factors into deteriorated tissue environments, senotherapeutics first rejuvenate the cardiac microenvironment by clearing cellular debris. This approach addresses why promising pre-clinical cardiac therapies have consistently failed in elderly patients—the aged heart's hostile environment sabotages regenerative interventions. The concept aligns with emerging longevity research showing senescent cell clearance extends healthspan across multiple organ systems. However, the authors don't specify which senotherapeutic compounds show the most cardiac promise, nor do they detail the mechanisms by which cleared senescent cells trigger endogenous regeneration. The paradigm-shifting insight is positioning senotherapeutics as essential adjuncts rather than standalone treatments, potentially transforming how we approach age-related heart failure in our rapidly aging population.